This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Golovine K , Makhov P , Uzzo RG , Kutikov A , Kaplan DJ , Fox E , Kolenko VM
Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-kappa B-independent, proteasome-mediated mechanism - art. no. 183
Molecular Cancer. 2010 Jul;9 :183-183
AbstractBackground: Cadmium has been classified as a human carcinogen, affecting health through occupational and environmental exposure. Cadmium has a long biological half-life (>25 years), due to the flat kinetics of its excretion. The prostate is one of the organs with highest levels of cadmium accumulation. Importantly, patients with prostate cancer appear to have higher levels of cadmium both in the circulation and in prostatic tissues. Results: In the current report, we demonstrate for the first time that cadmium down-regulates expression of the X-linked inhibitor of apoptosis protein (XIAP) in prostate cancer cells. Cadmium-mediated XIAP depletion occurs at the post-transcriptional level via an NF-kappa B-independent, proteasome-mediated mechanism and coincides with an increased sensitivity of prostate cancer cells to TNF-alpha-mediated apoptosis. Prolonged treatment with cadmium results in selection of prostate cancer cells with apoptosis-resistant phenotype. Development of apoptosis-resistance coincides with restoration of XIAP expression in cadmium-selected PC-3 cells. Conclusions: Selection of cadmium-resistant cells could represent an adaptive survival mechanism that may contribute to progression of prostatic malignancies.
NotesGolovine, Konstantin Makhov, Peter Uzzo, Robert G. Kutikov, Alexander Kaplan, David J. Fox, Eric Kolenko, Vladimir M. Biomed central ltd London 657zd